Investing.com - Xenon Pharmaceuticals (NASDAQ: XENE) reported third quarter EPS of $-0.73, $0.04 better than the analyst estimate of $-0.77. Revenue for the quarter came in at $0.00 versus the consensus estimate of $1.56M.
Xenon Pharmaceuticals's stock price closed at $32.15. It is down -14.72% in the last 3 months and down -2.75% in the last 12 months.
Xenon Pharmaceuticals saw 2 positive EPS revisions and 8 negative EPS revisions in the last 90 days. See Xenon Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Xenon Pharmaceuticals's Financial Health score is "fair performance".
Check out Xenon Pharmaceuticals's recent earnings performance, and Xenon Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar